Cited by 143Multiple Myeloma Research and TreatmentsPI3K/AKT/mTOR signaling in cancerAcute Myeloid Leukemia Research

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Open access

Spencer, Andrew, Yoon, Sung-Soo, Harrison, Simon J., Morris, Shannon R., Smith, Deborah A., Brigandi, Richard A., Gauvin, Jennifer, Kumar, Rakesh, Opalinska, Joanna B., Chen, Christine·2014·Blood

DOI 10.1182/blood-2014-03-559963PMC PMC4229853

Open this paper in CoChat — free account

Abstract

Key Points: Afuresertib has a favorable safety profile with manageable side effects and demonstrates single-agent activity against hematologic malignancies. Inhibition of AKT with afuresertib may provide a novel therapeutic strategy for hematologic malignancies, especially for multiple myeloma.

Integrity signals

Registry

Crossref · 10.1182/blood-2014-03-559963

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,452
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Hallek, M. J., Cheson, B. D., Catovsky, D., Caligaris‐Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,782
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Döhner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,686
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Multiple Myeloma
Palumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382
Multiple myeloma
Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Initial genome sequencing and analysis of multiple myeloma
Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C. L., Schinzel, A. C., Harview, C. L., Brunet, J.-P., Ahmann, G. J., Adli, M., et al. (2011) · Nature · doi:10.1038/nature09837 · Cited by 1,457
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Baccarani, M., Cortes, J. E., Pane, F., Niederwieser, D. W., Saglio, G. N., Apperley, J. F., Cervantes, F., Deininger, M. W., Gratwohl, A. A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,276

Show all 28 references

Sorted by citations

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,813
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
Jiang, N., Dai, Q., Su, X., Fu, J., Feng, X., & Peng, J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05435-1 · Cited by 577
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
LoRusso, P. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0018 · Cited by 473
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
Nițulescu, G. M., Margina, D. M., Juzenas, P., Peng, Q., Olaru, O. T., Saloustros, E. S., Fenga, C., Spandidos, D. A., Libra, M., & Tsatsakis, A. M. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3306 · Cited by 382
The Akt pathway in oncology therapy and beyond (Review)
Nițulescu, G. M., van de Venter, M., Nițulescu, G., Ungurianu, A., Juzenas, P., Peng, Q., Olaru, O. T., Grădinaru, D., Tsatsakis, A. M., Tsoukalas, D., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4597 · Cited by 331
Targeting AKT for cancer therapy
Shariati, M., & Meric‐Bernstam, F. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1676726 · Cited by 295
AKT in cancer: new molecular insights and advances in drug development
Mundi, P. S., Sachdev, J., McCourt, C., & Kalinsky, K. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13021 · Cited by 272
Applications of fluorine-containing amino acids for drug design
Mei, H., Han, J., Klika, K. D., Izawa, K., Sato, T., Meanwell, N. A., & Soloshonok, V. A. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111826 · Cited by 251
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 241
Maximising the potential of AKT inhibitors as anti-cancer treatments
Brown, J. S., & Banerji, U. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.12.001 · Cited by 222
Novel agents in the treatment of multiple myeloma: a review about the future
Naymagon, L., & Abdul‐Hay, M. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0282-1 · Cited by 180
Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation
Toulany, M., & Rodemann, H. P. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.07.003 · Cited by 174
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
Tolcher, A. W., Patnaik, A., Papadopoulos, K. P., Rasco, D. W., Becerra, C. R., Allred, A. J., Orford, K., Aktan, G., Ferron-Brady, G., Ibrahim, N., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2615-5 · Cited by 158
Self-citation
Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis
Wang, L., Liu, W., Broussy, S., Han, B., & Fang, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1307860 · Cited by 169
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 145
Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
Darici, S., Alkhaldi, H., Horne, G. A., Jørgensen, H. G., Marmiroli, S., & Huang, X. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092934 · Cited by 135
Recent advances in the pathobiology and management of Kasabach–Merritt phenomenon
O’Rafferty, C., O’Regan, G. M., Irvine, A. D., & Smith, O. P. (2015) · British Journal of Haematology · doi:10.1111/bjh.13557 · Cited by 128
Akt: a key transducer in cancer
Tsai, P., Lai, Y., Manne, R., Tsai, Y.-S., Sarbassov, D. D., & Lin, H. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00860-9 · Cited by 138
Multiple myeloma with high-risk cytogenetics and its treatment approach
Hanamura, I. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03353-5 · Cited by 126
Resistance to proteasome inhibitors and other targeted therapies in myeloma
Wallington-Beddoe, C. T., Sobieraj‐Teague, M., Kuss, B. J., & Pitson, S. M. (2018) · British Journal of Haematology · doi:10.1111/bjh.15210 · Cited by 112
Novel therapeutic strategies for multiple myeloma
Mimura, N., Hideshima, T., & Anderson, K. C. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.04.010 · Cited by 110
PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise
Ramakrishnan, V. G., & Kumar, S. K. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1421760 · Cited by 94
Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis
Kim, M., Baek, M., & Kim, D. J. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170616082125 · Cited by 92
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments
Hu, J., & Hu, W.-X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.020 · Cited by 84
Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma
Zhang, X., Lee, H. C., Shirazi, F., Baladandayuthapani, V., Lin, H. Y., Kuiatse, I., Wang, H., Jones, R. J., Berkova, Z., Singh, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0044-x · Cited by 86
Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management
Goldman, J. W., Mendenhall, M. A., & Rettinger, S. R. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0519 · Cited by 83
Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt
Uhlenbrock, N., Smith, S. P., Weisner, J., Landel, I., Lindemann, M., Le, T. A., Hardick, J., Gontla, R., Scheinpflug, R., Czodrowski, P., et al. (2019) · Chemical Science · doi:10.1039/c8sc05212c · Cited by 84
Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
Gautam, P., Karhinen, L., Szwajda, A., Jha, S. K., Yadav, B., Aittokallio, T. A., & Wennerberg, K. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0517-3 · Cited by 66
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Blagden, S. P., Hamilton, A. L., Mileshkin, L., Wong, S., Michael, A., Hall, M., Goh, J. C. H., Lisyanskaya, A. S., DeSilvio, M., Frangou, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2277 · Cited by 65
Keratin 80 promotes migration and invasion of colorectal carcinoma by interacting with PRKDC via activating the AKT pathway
Li, C., Liu, X., Liu, Y., Liu, X., Wang, R., Liao, J., Wu, S., Fan, J., Peng, Z., Li, B., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1030-y · Cited by 60
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
Aghajanian, C. A., Bell‐McGuinn, K. M., Burris, H. A., Siu, L. L., Stayner, L.-A., Wheler, J. J., Hong, D. S., Kurkjian, C. D., Pant, S., Santiago-Walker, A., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0591-z · Cited by 58
Self-citation
Molecular target: pan-AKT in gastric cancer
Kang, B. W., & Chau, I. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000728 · Cited by 57
CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the Kit-, Ras/Raf/Erk- and Akt-pathways
Schulte, S., Waha, A., Steiger, B., Denkhaus, D., Dörner, E., Calaminus, G., Leuschner, I., & Pietsch, T. (2016) · Oncotarget · doi:10.18632/oncotarget.10392 · Cited by 56
The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies
Harding, T., Baughn, L. B., Kumar, S. K., & Ness, B. V. (2019) · Leukemia · doi:10.1038/s41375-018-0362-z · Cited by 56
Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment
Bolomsky, A., Schlangen, K., Schreiner, W., Zojer, N., & Ludwig, H. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0247-4 · Cited by 54
Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Puła, B., Gołoś, A., Górniak, P., & Jamroziak, K. (2019) · Cancers · doi:10.3390/cancers11121834 · Cited by 52
Phosphorylation-Dependent Inhibition of Akt1
Balasuriya, N., McKenna, M., Liu, X., Li, S. S. ‐., & O’Donoghue, P. (2018) · Genes · doi:10.3390/genes9090450 · Cited by 50
Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises
Pervanidis, K. A., D’Angelo, G. D., Weisner, J., Brandherm, S., & Rauh, D. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00075 · Cited by 52
Crosstalk between HSPA5 arginylation and sequential ubiquitination leads to AKT degradation through autophagy flux
Kim, H. J., Kim, S., Kim, D.-H., Park, J. S., Jeong, S. H., Choi, Y. W., & Kim, C. (2020) · Autophagy · doi:10.1080/15548627.2020.1740529 · Cited by 48
Emerging drugs and combinations to treat multiple myeloma
Larocca, A., Mina, R., Gay, F., Bringhen, S., & Boccadoro, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19269 · Cited by 44
Phospho-Form Specific Substrates of Protein Kinase B (AKT1)
McKenna, M., Balasuriya, N., Zhong, S., Li, S. S. ‐., & O’Donoghue, P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.619252 · Cited by 46
Parkin Facilitates Proteasome Inhibitor-Induced Apoptosis via Suppression of NF-κB Activity in Hepatocellular Carcinoma
Zhang, X., Lin, C., Song, J., Chen, H., Chen, X., Ren, L., Zhou, Z., Pan, J., Yang, Z., Bao, W., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1881-x · Cited by 43
Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)
Huang, X., You, L., Nepovimová, E., Psotka, M., Maliňák, D., Valko, M., Sivák, L., Korábečný, J., Heger, Z., Adam, V., et al. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2237209 · Cited by 44
Luteolin inhibits triple-negative breast cancer by inducing apoptosis and autophagy through SGK1-FOXO3a-BNIP3 signaling
Wu, L., Lin, Y., Gao, S., Wang, Y., Pan, H., Wang, Z., Pozzolini, M., Yang, F., Zhang, H., Yang, Y. L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1200843 · Cited by 41
Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis : An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases
Mahon, R. N., & Hafner, R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ621 · Cited by 37
Pathway-Directed Therapy in Multiple Myeloma
John, L., Krauth, M. T., Podar, K., & Raab, M. (2021) · Cancers · doi:10.3390/cancers13071668 · Cited by 33
Medication-induced hyperglycemia and diabetes mellitus: a review of current literature and practical management strategies
Jain, A. B., & Lai, V. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01628-0 · Cited by 32
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)
Sabbah, D. A., Hajjo, R., Bardaweel, S. K., & Zhong, H. A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2338100 · Cited by 34
Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors
Zhan, W., Xu, L., Dong, X., Dong, J., Yi, X., Ma, X., Qiu, N., Li, J. X., Yang, B., Zhou, Y., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.074 · Cited by 31
Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers
Shan, K. S., Bonano-Rios, A. M., Theik, N. W. Y., Hussein, A. M., & Blaya, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041973 · Cited by 31
Drug targets and resistance mechanisms in multiple myeloma
Naß, J., & Efferth, T. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.04 · Cited by 28
Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies
Kumar, S. K. (2017) · Hematology · doi:10.1182/asheducation-2017.1.518 · Cited by 27
Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma
Eichner, R., Fernández‐Sáiz, V., Targosz, B., & Bassermann, F. C. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.06.001 · Cited by 27
Novel Agents in Multiple Myeloma
Szalat, R. E., & Munshi, N. C. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000355 · Cited by 27
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK
Dean, E. J., Banerji, U., Schellens, J. H. M., Krebs, M., Jiménez, B., van Brummelen, E. M. J., Bailey, C., Casson, E., Cripps, D., Cullberg, M., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3558-z · Cited by 26
OTUB2 regulates KRT80 stability via deubiquitination and promotes tumour proliferation in gastric cancer
Ouyang, S., Zeng, Z., Liu, Z., Zhang, Z., Sun, J., Wang, X., Ma, M., Ye, X., Yu, J., & Kang, W. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00839-3 · Cited by 25
NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma
Yen, C., & Hsiao, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113503 · Cited by 25
Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma
Hirano, M., Imai, Y., Kaito, Y., Murayama, T., Sato, K., Ishida, T., Yamamoto, J., Ito, T., Futami, M., Ri, M., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01909-7 · Cited by 25
Emerging protein kinase inhibitors for the treatment of multiple myeloma
Lind, J., Czernilofsky, F., Vallet, S., & Podar, K. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1647165 · Cited by 25
A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis
Arceci, R. J., Allen, C. E., Dunkel, I. J., Jacobsen, E. D., Whitlock, J. A., Vassallo, R., Morris, S. R., Portnoy, A., Reedy, B. A., Smith, D. A., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26325 · Cited by 24
Self-citation
Kinase inhibitors as potential agents in the treatment of multiple myeloma
Abramson, H. N. (2016) · Oncotarget · doi:10.18632/oncotarget.10745 · Cited by 23
Recent Advance of Akt Inhibitors in Clinical Trials
Guo, K., Tang, W., Zhuo, H., & Zhao, G. (2019) · ChemistrySelect · doi:10.1002/slct.201901293 · Cited by 23
Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Ni, H., Shirazi, F., Baladandayuthapani, V., Lin, H. Y., Kuiatse, I., Wang, H., Jones, R. J., Berkova, Z., Hitoshi, Y., Ansell, S. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3265 · Cited by 22
Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation
Okabe, S., Tanaka, Y., Tauchi, T., & Ohyashiki, K. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3547-7 · Cited by 21
Cbl-b Is Upregulated and Plays a Negative Role in Activated Human NK Cells
Lu, T., Chen, L., Mansour, A. G., Yu, M., Brooks, N., Teng, K., Li, Z., Zhang, J., Barr, T., Yu, J., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000177 · Cited by 20
Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities
Zhang, J., Park, D., Shin, D. M., & Deng, X. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv118 · Cited by 20
Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma
Brünnert, D., Kraus, M., Stühmer, T., Kirner, S., Heiden, R., Goyal, P., Driessen, C., Bargou, R. C., & Chatterjee, M. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.04.003 · Cited by 18
Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS
Müller, E., Bauer, S., Stühmer, T., Mottok, A., Scholz, C. J., Steinbrunn, T., Brünnert, D., Brandl, A., Schraud, H., Kressmann, S., et al. (2016) · Leukemia · doi:10.1038/leu.2016.264 · Cited by 17
Novel investigational drugs active as single agents in multiple myeloma
D’Agostino, M., Salvini, M., Palumbo, A. P., Larocca, A., & Gay, F. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1324571 · Cited by 16
Targeting the Ras pathway in pediatric hematologic malignancies
Pikman, Y., & Stieglitz, E. (2020) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000981 · Cited by 15
Identification and development of a subtype-selective allosteric AKT inhibitor suitable for clinical development
Page, N., Wappett, M., O'Dowd, C. R., O’Rourke, M., Gavory, G., Zhang, L., Rountree, J. S. S., Jordan, L., Barker, O., Gibson, H., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20208-5 · Cited by 15
Selectivity Studies and Free Energy Calculations of AKT Inhibitors
Zhong, H. A., & Goodwin, D. T. (2024) · Molecules · doi:10.3390/molecules29061233 · Cited by 16
Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1
Mahajan, P., Wadhwa, B., Barik, M. R., Malik, F. A., & Nargotra, A. (2019) · Molecular Diversity · doi:10.1007/s11030-019-09924-9 · Cited by 15
AKT1 Promotes Tumorigenesis and Metastasis by Directly Phosphorylating Hexokinases
Yu, Y., Wang, S., Wang, Y., Zhang, Q., Zhao, L., Wang, Y., Wu, J., Han, L., Wang, J., Guo, J., et al. (2024) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30613 · Cited by 14
Potent antitumor effect of combination therapy with sub‑optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma
Kinoshita, S., Ri, M., Kanamori, T., Aoki, S., Yoshida, T., Narita, T., Totani, H., Ito, A., Kusumoto, S., Ishida, T., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.8501 · Cited by 14
ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF‐κB in multiple myeloma
Jiang, J., Sun, Y., Xu, J., Xu, T., Zhao, X., & Liu, P. (2020) · Cancer Medicine · doi:10.1002/cam4.3347 · Cited by 12
Pathogenic signaling in multiple myeloma
Bolomsky, A., & Young, R. M. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.005 · Cited by 15
PDK1 inhibitor GSK2334470 synergizes with proteasome inhibitor MG‑132 in multiple myeloma cells by inhibiting full AKT activity and increasing nuclear accumulation of the PTEN protein
Zhang, J., Yang, C., Zhou, F., & Chen, X. (2018) · Oncology Reports · doi:10.3892/or.2018.6369 · Cited by 12
Emerging serine-threonine kinase inhibitors for treating ovarian cancer
Maoz, A., Ciccone, M. A., Matsuzaki, S., Coleman, R. L., & Matsuo, K. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1696773 · Cited by 12
Metabolic modeling-based drug repurposing in Glioblastoma
Tomi-Andrino, C., Pandele, A., Winzer, K., King, J. R., Rahman, R., & Kim, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-14721-w · Cited by 11
Advances in the Understanding of Akt Signaling in Cancers and the Potential of Inhibiting Akt-Driven Tumors Using Small Molecule Inhibitors: An Overview
Aswathanarayan, J. B., Naaz, R., Doreswamy, S. H., Karnik, M., Kumar, S. M. N., Sreenivasan, A., Sharma, A. K., & Madhunapantula, S. V. (2026) · Cancers · doi:10.3390/cancers18040578 · Cited by 11
Resibufogenin inhibits the malignant characteristics of multiple myeloma cells by blocking the PI3K/Akt signaling pathway
Zhou, Y., Hong, Z., Jin, K., Lin, C., Xiang, J., Ge, H., Zheng, Z., Shen, J., & Deng, S. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11368 · Cited by 10
A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*
Chen, C. I., Paul, H. K., Le, L. W., Wei, E. N., Snitzler, S., Wang, T., Levina, O., Kakar, S., Lau, A., Queau, M. L., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1468892 · Cited by 10
Self-citation
The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL‐1 cell growth
Wu, J. H., Limmer, A. L., Narayanan, D., Doan, H. Q., Simonette, R. A., Rady, P. L., & Tyring, S. K. (2021) · Clinical and Experimental Dermatology · doi:10.1111/ced.14798 · Cited by 10
Pathogenesis of central nervous system germ cell tumors
Liu, S. J., Ren, L., Gao, X. J., Hao, M., & Wang, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.991484 · Cited by 10
Targeting Molecular Signaling Pathways and Cytokine Responses to Modulate c-MYC in Acute Myeloid Leukemia
Gu, K. J., May, H. A., & Kang, M. H. (2024) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1603015 · Cited by 9
Future Developments in the Treatment of AL Amyloidosis
Theodorakakou, F., Fotiou, D., Dimopoulos, M. A., & Kastritis, E. (2022) · Hemato · doi:10.3390/hemato3010012 · Cited by 9
Pancreatic Hormone Insulin Modulates Organic Anion Transporter 1 in the Kidney: Regulation via Remote Sensing and Signaling Network
Yu, Z., Zhang, J., Liang, Z., Wu, J., Liu, K., & You, G. (2023) · The AAPS Journal · doi:10.1208/s12248-022-00778-y · Cited by 10
Targeting Akt Signaling Pathway in Cancer: Molecular Mechanisms and Advances in Therapeutic Interventions
Leiphrakpam, P. D., Batra, R., Tenner, L. L., & Are, C. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl39100 · Cited by 10
SPAG5 as a novel biomarker and potential therapeutic target via regulating AKT pathway in multiple myeloma
Zeng, X., Xu, W., Tong, J., Liu, J., Zhang, Z., Liu, M., Wu, C., Yu, Q., Ye, C., Wu, C., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2086247 · Cited by 8
Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies
Boutilier, A. J., Huang, L., & Elsawa, S. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911145 · Cited by 11
Screening of PI3K-Akt-targeting Drugs for Silkworm against Bombyx mori Nucleopolyhedrovirus
Wang, B., Jiang, L., Guo, H., Sun, Q., Wang, Y., Xie, E., & Xia, Q. (2019) · Molecules · doi:10.3390/molecules24071260 · Cited by 8
Gld2 activity is regulated by phosphorylation in the N-terminal domain
Chung, C. Z., Balasuriya, N., Manni, E., Liu, X., Li, S. S. ‐., O’Donoghue, P., & Heinemann, I. U. (2019) · RNA Biology · doi:10.1080/15476286.2019.1608754 · Cited by 9
Novel furo[2,3- d ]pyrimidine derivatives as PI3K/AKT dual inhibitors: design, synthesis, biological evaluation, and molecular dynamics simulation
Reheim, M. A. M. A., Elgammal, W. E., Bashandy, M. S., Hamed, M. I. A., AboulMagd, A. M., Khalil, M. G., Abdou, A. M., & Hassan, R. A. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00139k · Cited by 6
Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives
Barreto, I. V., Machado, C. B., Almeida, D. B., Pessoa, F. M. C. D. P., Gadelha, R. B., Pantoja, L. D. C., Oliveira, D. D. S., Ribeiro, R. M., Lopes, G. S., de Moraes, M. O., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091784 · Cited by 6
Targeting AKT2 in MDA‐MB‐231 Cells by Pyrazole Hybrids: Structural, Biological and Molecular Docking Studies
Gaikwad, S. S., Nimal, S. K., Pol, R., Markad, D., Jadhao, A. R., Jadhav, U. U., Kate, A. N., Gacche, R. N., Patil, L. R., & Chikate, R. C. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202300799 · Cited by 6
Novel Systemic Approaches for the Management of Meningiomas
Ijad, N., Dahal, A., Kim, A. E., Wakimoto, H., Juratli, T. A., & Brastianos, P. K. (2023) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2023.02.012 · Cited by 5
Akt inhibitors in cancer therapy
Alam, M., Ali, S., & Hassan, M. I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91287-7.00006-5 · Cited by 6

Authors: Spencer, A., Yoon, S.-S., Harrison, S. J., Morris, S. R., Smith, D. A., Brigandi, R. A., Gauvin, J., Kumar, R., Opalinska, J. B., & Chen, C.
Affiliations: The Alfred Hospital (AU)
Seoul National University Hospital (KR)
The University of Melbourne (AU)
GlaxoSmithKline (United States) (US)
Princess Margaret Cancer Centre (CA)
ORCID: Spencer, Andrew
Yoon, Sung-Soo
Harrison, Simon J.
Smith, Deborah A.
Brigandi, Richard A.
Kumar, Rakesh
Chen, Christine
Venue: Blood
Publisher: American Society of Hematology
Published: 2014-10-02
Volume: 124
Issue: 14
Pages: 2190-2195
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2014-03-559963
PMC: PMC4229853
OpenAlex: W2094611598
Cited by: 142
References: 28
Citations by year: 2026: 5 · 2025: 13 · 2024: 12 · 2023: 7 · 2022: 15 · 2021: 11 · 2020: 9 · 2019: 17 · 2018: 17 · 2017: 11 · 2016: 13 · 2015: 10 · 2014: 2
FWCI: 8.75
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Blood (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: GlaxoSmithKline
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords: AKT inhibitors, multiple myeloma, PI3K/Akt signaling, hematologic malignancies, maximum tolerated dose, pharmacokinetics, safety, adverse events, non-Hodgkin lymphoma, Langerhans cell histiocytosis, Hodgkin's disease, drug resistance
MeSH terms: Administration, Oral, Adolescent, Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Multiple Myeloma, Pyrazoles, Thiophenes, Time Factors, Hematologic Neoplasms, Maximum Tolerated Dose, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Young Adult, Patient Safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks